Hirashima Masaki, Imamura Takayuki, Yano Kentaro, Kawamura Ryoichi, Meta Akihiro, Tokieda Yoshiyuki, Nakashima Toshihiro
R&D Division; and.
Blood Plasma Division, The Chemo-Sero-Therapeutic Research Institute, KAKETSUKEN, 1314-1 Kyokushi-Kawabe, Kikuchi, Kumamoto 869-1298, Japan.
J Biochem. 2016 Feb;159(2):261-70. doi: 10.1093/jb/mvv099. Epub 2015 Oct 15.
Fibrinogen is a large and complex glycoprotein containing two sets of each of three different chains (α, β and γ). There have been no reports of high-level expression of fibrinogen at commercial levels using mammalian cultured cells such as CHO cells because of the difficulty in highly expressing a protein with such a complex structure. We achieved high-level (1.3 g/l or higher) expression of recombinant human fibrinogen using CHO DG44 cells by optimizing the expression system and culture conditions. We also succeeded in establishing a high-recovery preparation method for recombinant fibrinogen that rarely yields degraded products. To characterize the properties of the recombinant human fibrinogen, we performed SDS-PAGE; western blotting of the α, β and γ chains using specific antibodies and scanning electron microscopy observations of fibrin fibres. We also evaluated the functional equivalence between recombinant fibrinogen and plasma fibrinogen with respect to the release of fibrinopeptides initiated by thrombin and its cross-linking properties. The basic properties of recombinant fibrinogen showed no apparent differences from those of plasma fibrinogen. Here, we report the development of methods for the culture and preparation of recombinant human fibrinogen of satisfactory quality that can be scaled up to the commercial level.
纤维蛋白原是一种大型复杂糖蛋白,由三种不同链(α、β和γ)各两套组成。由于难以在哺乳动物培养细胞(如CHO细胞)中高水平表达结构如此复杂的蛋白质,目前尚无关于利用此类细胞实现商业水平的纤维蛋白原高水平表达的报道。我们通过优化表达系统和培养条件,利用CHO DG44细胞实现了重组人纤维蛋白原的高水平(1.3 g/l或更高)表达。我们还成功建立了一种重组纤维蛋白原的高回收率制备方法,该方法很少产生降解产物。为了表征重组人纤维蛋白原的特性,我们进行了SDS-PAGE、使用特异性抗体对α、β和γ链进行蛋白质印迹以及对纤维蛋白纤维进行扫描电子显微镜观察。我们还评估了重组纤维蛋白原与血浆纤维蛋白原在凝血酶引发的纤维蛋白肽释放及其交联特性方面的功能等效性。重组纤维蛋白原的基本特性与血浆纤维蛋白原相比无明显差异。在此,我们报告了可扩大至商业规模的、用于培养和制备质量令人满意的重组人纤维蛋白原的方法的开发情况。